TNYA Stock Overview
A biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tenaya Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.06 |
| 52 Week High | US$7.01 |
| 52 Week Low | US$0.99 |
| Beta | 2.9 |
| 1 Month Change | -30.26% |
| 3 Month Change | -50.23% |
| 1 Year Change | -75.06% |
| 3 Year Change | -92.17% |
| 5 Year Change | n/a |
| Change since IPO | -93.09% |
Recent News & Updates
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely
Jan 23
Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease
Dec 30Recent updates
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely
Jan 23Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease
Dec 30Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Sep 18We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
Jun 04Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Dec 20Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely
Mar 07Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?
Dec 06Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment
Sep 06Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07
Aug 10Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely
Mar 03Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth
Nov 01Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms
Aug 06Shareholder Returns
| TNYA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | 0.9% | 0.4% |
| 1Y | -75.1% | -2.1% | 23.1% |
Return vs Industry: TNYA underperformed the US Biotechs industry which returned -2.1% over the past year.
Return vs Market: TNYA underperformed the US Market which returned 23.1% over the past year.
Price Volatility
| TNYA volatility | |
|---|---|
| TNYA Average Weekly Movement | 24.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TNYA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TNYA's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 140 | Faraz Ali | www.tenayatherapeutics.com |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
Tenaya Therapeutics, Inc. Fundamentals Summary
| TNYA fundamental statistics | |
|---|---|
| Market cap | US$83.97m |
| Earnings (TTM) | -US$117.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs TNYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNYA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$117.23m |
| Earnings | -US$117.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TNYA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 07:52 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tenaya Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Emanuela Branchetti | H.C. Wainwright & Co. |